J&J to acquire Ambrx Biopharma, a cancer drug developer, for $2B
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August…
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new…